Mass spectrometric approaches to protein ADP-ribosylation

蛋白质 ADP 核糖基化的质谱方法

基本信息

  • 批准号:
    9568790
  • 负责人:
  • 金额:
    $ 30.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-30 至 2021-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary Poly-ADP-ribosylation (PARylation) is a protein posttranslational modification (PTM) that was first documented in 1963. PARylation is catalyzed by a family of enzymes called Poly-ADP-ribose polymerases (PARPs). In particular, PARP1 is a nuclear protein that is activated as a result of sensing DNA strand breaks. The PARylation level in a quiescent cell is usually very low. In response to genotoxic stress, PARP1 is recruited to nicked DNA and is rapidly activated, resulting in the synthesis of a large number of PARylated proteins and initiation of the DNA damage repair mechanisms. The critical roles of PARP1 in mediating DNA repair and also cell death provide the rationale for developing PARP1 inhibitors to treat a number of human diseases, including cancer and ischemic stroke. In particular, cancer cells with defects in double-strand break (DSB) repair, such as BRCA1/2-mutated cells, are reliant on PARP1 activity for genome integrity. These cells undergo unsustainable genetic damage upon PARP1 inhibition. Indeed, late-stage clinical studies revealed that PARP1 inhibitor treatment significantly prolonged progression-free survival of BRCA-deficient ovarian cancer patients. This led to its recent approval by the FDA. Contrary to the fruitful efforts of characterizing the upstream regulators of PARP1, its genuine downstream targets are poorly defined, which has significantly hampered its further functional study. In particular, site-localization of protein PARylation remains a daunting challenge, due to its labile and heterogeneous nature. To address these pressing questions, we developed a large-scale mass spectrometric approach towards comprehensive characterization of the Asp- and Glu-PARylated proteome. We identified a total of 1,048 unique, endogenously modified D/E-PARylation sites on 340 proteins. These proteins are involved in not only DNA damage repair, but also a surprisingly wide array of other nuclear functions. Using a quantitative mass spectrometry experiment, we also identified many previously unknown PARP1 downstream targets, whose PARylation is sensitive to clinically relevant PARP1 inhibitors. In this proposal, we will leverage these preliminary results to continue to characterize protein ADP-ribosylation, with a long term goal of comprehensively understanding the role of PARPs and ADP-ribosylation in various pathophysiological processes. The specific aims of our proposed work are to: (1) develop a large-scale approach to site-specific characterization of the D/E-mono-ADP-ribosylated proteome; (2) develop a large- scale method to measure absolute protein PARylation stoichiometries; and (3) develop a chemoproteomic approach to systemically investigating the specificity of clinically relevant PARP1 inhibitors. We will accomplish our goals with a multi-disciplinary approach, utilizing tools including proteomics, chemical biology, biochemistry, bioinformatics and molecular biology. Knowledge we garner in this proposal will also have a profound impact on how to further explore PARPs as potential therapeutic targets for treating human diseases.
项目摘要 聚ADP核糖基化(PARylation)是一种首次被记录的蛋白质翻译后修饰(PTM) 1963年PAR化由称为聚ADP-核糖聚合酶(PARP)的酶家族催化。在 特别地,PARP 1是作为感应DNA链断裂的结果而被激活的核蛋白。的 静止细胞中的PAR化水平通常非常低。在对遗传毒性应激的反应中,PARP 1被募集, 切割DNA并迅速活化,导致大量PAR化蛋白质的合成, 启动DNA损伤修复机制。PARP 1在介导DNA修复中的关键作用, 细胞死亡提供了开发PARP 1抑制剂以治疗许多人类疾病的基本原理,包括 癌症和缺血性中风。特别是,具有双链断裂(DSB)修复缺陷的癌细胞,如 作为BRCA 1/2突变的细胞,依赖于PARP 1活性来保持基因组的完整性。这些细胞经历 对PARP 1抑制的不可持续的遗传损伤。事实上,后期临床研究表明,PARP 1 抑制剂治疗显著延长BRCA缺陷卵巢癌患者的无进展生存期。 这使得它最近获得了FDA的批准。与描绘上游的富有成效的努力相反, PARP 1的监管机构,其真正的下游目标定义不清,这大大阻碍了其 进一步的功能研究。特别是,蛋白质PAR化的位点定位仍然是一个艰巨的挑战, 它的不稳定性和异质性。为了解决这些紧迫的问题,我们开发了一个大规模的质量 光谱方法对全面表征的Asp和Glu-PAR化的蛋白质组。 我们在340种蛋白质上鉴定了总共1,048个独特的内源性修饰的D/E-PAR化位点。这些 蛋白质不仅参与DNA损伤的修复,而且还参与一系列令人惊讶的其他核蛋白的修复。 功能协调发展的使用定量质谱实验,我们还发现了许多以前未知的 PARP 1下游靶点,其PAR化对临床相关PARP 1抑制剂敏感。在这 建议,我们将利用这些初步结果继续表征蛋白质ADP-核糖基化, 长期目标是全面了解PARP和ADP-核糖基化在各种 病理生理过程我们建议的工作的具体目标是:(1)开发一个大规模的 D/E-单-ADP-核糖基化蛋白质组的位点特异性表征方法;(2)开发一个大的 规模的方法来测量绝对蛋白质PAR化化学计量;和(3)开发一种化学蛋白质组学方法, 系统研究临床相关PARP 1抑制剂特异性的方法。要全面完成 我们的目标与多学科的方法,利用包括蛋白质组学,化学生物学,生物化学, 生物信息学和分子生物学。我们在这份提案中获得的知识也将产生深远的影响, 如何进一步探索PARP作为治疗人类疾病的潜在治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yonghao Yu其他文献

Yonghao Yu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yonghao Yu', 18)}}的其他基金

A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
  • 批准号:
    10524783
  • 财政年份:
    2022
  • 资助金额:
    $ 30.58万
  • 项目类别:
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
  • 批准号:
    10610165
  • 财政年份:
    2022
  • 资助金额:
    $ 30.58万
  • 项目类别:
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
  • 批准号:
    10389853
  • 财政年份:
    2021
  • 资助金额:
    $ 30.58万
  • 项目类别:
Site-Specific Antibody for Protein Poly-ADP-Ribosylation
蛋白质聚 ADP 核糖基化位点特异性抗体
  • 批准号:
    10610163
  • 财政年份:
    2021
  • 资助金额:
    $ 30.58万
  • 项目类别:
Site-Specific Antibody for Protein Poly-ADP-Ribosylation
蛋白质聚 ADP 核糖基化位点特异性抗体
  • 批准号:
    10231962
  • 财政年份:
    2021
  • 资助金额:
    $ 30.58万
  • 项目类别:
Posttranslational Regulation of Cell Growth and Stress Responses
细胞生长和应激反应的翻译后调节
  • 批准号:
    10676253
  • 财政年份:
    2020
  • 资助金额:
    $ 30.58万
  • 项目类别:
Posttranslational Regulation of Cell Growth and Stress Responses
细胞生长和应激反应的翻译后调节
  • 批准号:
    10610164
  • 财政年份:
    2020
  • 资助金额:
    $ 30.58万
  • 项目类别:
Molecular and Biochemical Basis of mTORC1-mediated Feedback Loops
mTORC1 介导的反馈环的分子和生化基础
  • 批准号:
    9143156
  • 财政年份:
    2015
  • 资助金额:
    $ 30.58万
  • 项目类别:
Molecular and Biochemical Basis of mTORC1-mediated Feedback Loops
mTORC1 介导的反馈环的分子和生化基础
  • 批准号:
    9341365
  • 财政年份:
    2015
  • 资助金额:
    $ 30.58万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.58万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了